Restenosis after percutaneous coronary intervention is associated with the angiotensin-II type-1 receptor 1166A/C polymorphism but not with polymorphisms of angiotensin-converting enzyme, angiotensin-II receptor, angiotensinogen or heme oxygenase-1

JS Wijpkema; PL van Haelst; PS Monraats; M Bruinenberg; AH Zwinderman; F Zijlstra; G van der Steege; RJ de Winter; PAFM Doevendans; J Waltenberger; JW Jukema; RA Tio

Restenosis after percutaneous coronary intervention is associated with the angiotensin-II type-1 receptor 1166A/C polymorphism but not with polymorphisms of angiotensin-converting enzyme, angiotensin-II receptor, angiotensinogen or heme oxygenase-1

JS Wijpkema, PL van Haelst, PS Monraats, M Bruinenberg, AH Zwinderman, F Zijlstra, G van der Steege, RJ de Winter, PAFM Doevendans, J Waltenberger, JW Jukema, RA Tio^*

^*Corresponding author voor dit werk

Onderzoeksoutput: Article › Academic › peer review

30 Citaten (Scopus)

Samenvatting

Objectives The renin-angiotensin system (RAS) is thought to play a major role in the pathophysiology of de-novo restenotic lesions and in-stent restenosis after percutaneous coronary intervention (PCI). Heme oxygenase-1 (HO-1), is thought to beneficially influence these processes. We examined the effect of pharmacologic as well as genetic RAS interactions on restenosis in a large population of consecutive patients undergoing PCI, and evaluated possible gene-gene interactions in both systems.

Methods The GENDER project is a multicenter prospective follow-up study, including 3146 patients after successful PCI. Genotyping in these patients was performed for the ACE gene insertion/deletion, the angiotensinogen 235Met/Thr, T174M and A(-6)G, the angiotensin-II type 1 receptor (AT1R) 1166A/C and T81OA, the angiotensin-II type 2 receptor (AT2R) 1675G/A and 3123A polymorphisms and the length polymorphism in the HO-1 promoter region.

Results A total of 3104 patients were followed for 10 months. In 2975 patients at least one of the nine genotypes could be determined. The AT1R 1166 CC genotype showed a significant association with TVR; the other polymorphisms did not. RAS-inhibitory drugs were not associated with the incidence of TVR, nor did they interact with any of the investigated polymorphisms. Patients with the ACE I/I polymorphism showed a trend towards a better outcome if they had a short number of repeats in the HO-1 promoter. This relationship was inversely present in carriers of the ACE D/D polymorphism.

Conclusion We could only establish a role for the AT1R 1166A/C polymorphism in restenosis after PCI. However, significant gene-gene interaction was suggested for the ACE gene and the HO-1 promotor. The RAS and HO-1 relation in restenosis merits further investigation. Pharmacogenetics and Genomics 16:331-337 (c) 2006 Lippincott Williams & Wilkins.

Originele taal-2	English
Pagina's (van-tot)	331-337
Aantal pagina's	7
Tijdschrift	PHARMACOGENETICS AND GENOMICS
Volume	16
Nummer van het tijdschrift	5
Status	Published - mei-2006

Handle.net

Permanente koppeling

Vingerafdruk

Duik in de onderzoeksthema's van 'Restenosis after percutaneous coronary intervention is associated with the angiotensin-II type-1 receptor 1166A/C polymorphism but not with polymorphisms of angiotensin-converting enzyme, angiotensin-II receptor, angiotensinogen or heme oxygenase-1'. Samen vormen ze een unieke vingerafdruk.

Citeer dit

Wijpkema, JS., van Haelst, PL., Monraats, PS., Bruinenberg, M., Zwinderman, AH., Zijlstra, F., van der Steege, G., de Winter, RJ., Doevendans, PAFM., Waltenberger, J., Jukema, JW., & Tio, RA. (2006). Restenosis after percutaneous coronary intervention is associated with the angiotensin-II type-1 receptor 1166A/C polymorphism but not with polymorphisms of angiotensin-converting enzyme, angiotensin-II receptor, angiotensinogen or heme oxygenase-1. PHARMACOGENETICS AND GENOMICS, 16(5), 331-337.

Wijpkema, JS ; van Haelst, PL ; Monraats, PS et al. / Restenosis after percutaneous coronary intervention is associated with the angiotensin-II type-1 receptor 1166A/C polymorphism but not with polymorphisms of angiotensin-converting enzyme, angiotensin-II receptor, angiotensinogen or heme oxygenase-1. In: PHARMACOGENETICS AND GENOMICS. 2006 ; Vol. 16, Nr. 5. blz. 331-337.

@article{4183e1630d2e4c3ebce2dabb8aab98ab,

title = "Restenosis after percutaneous coronary intervention is associated with the angiotensin-II type-1 receptor 1166A/C polymorphism but not with polymorphisms of angiotensin-converting enzyme, angiotensin-II receptor, angiotensinogen or heme oxygenase-1",

abstract = "Objectives The renin-angiotensin system (RAS) is thought to play a major role in the pathophysiology of de-novo restenotic lesions and in-stent restenosis after percutaneous coronary intervention (PCI). Heme oxygenase-1 (HO-1), is thought to beneficially influence these processes. We examined the effect of pharmacologic as well as genetic RAS interactions on restenosis in a large population of consecutive patients undergoing PCI, and evaluated possible gene-gene interactions in both systems.Methods The GENDER project is a multicenter prospective follow-up study, including 3146 patients after successful PCI. Genotyping in these patients was performed for the ACE gene insertion/deletion, the angiotensinogen 235Met/Thr, T174M and A(-6)G, the angiotensin-II type 1 receptor (AT1R) 1166A/C and T81OA, the angiotensin-II type 2 receptor (AT2R) 1675G/A and 3123A polymorphisms and the length polymorphism in the HO-1 promoter region.Results A total of 3104 patients were followed for 10 months. In 2975 patients at least one of the nine genotypes could be determined. The AT1R 1166 CC genotype showed a significant association with TVR; the other polymorphisms did not. RAS-inhibitory drugs were not associated with the incidence of TVR, nor did they interact with any of the investigated polymorphisms. Patients with the ACE I/I polymorphism showed a trend towards a better outcome if they had a short number of repeats in the HO-1 promoter. This relationship was inversely present in carriers of the ACE D/D polymorphism.Conclusion We could only establish a role for the AT1R 1166A/C polymorphism in restenosis after PCI. However, significant gene-gene interaction was suggested for the ACE gene and the HO-1 promotor. The RAS and HO-1 relation in restenosis merits further investigation. Pharmacogenetics and Genomics 16:331-337 (c) 2006 Lippincott Williams & Wilkins.",

keywords = "angiotensins, renin-angiotensin system, hemeoxygenase 1, single nucleotide polymorphism, coronary restenosis, angioplasty, PLACEBO-CONTROLLED TRIAL, MICROSATELLITE POLYMORPHISM, ARTERY DISEASE, BLOOD-PRESSURE, GENE PROMOTER, BALLOON ANGIOPLASTY, RISK-FACTORS, DOUBLE-BLIND, IN-VIVO, SYSTEM",

author = "JS Wijpkema and {van Haelst}, PL and PS Monraats and M Bruinenberg and AH Zwinderman and F Zijlstra and {van der Steege}, G and {de Winter}, RJ and PAFM Doevendans and J Waltenberger and JW Jukema and RA Tio",

note = "0 Article J",

year = "2006",

month = may,

language = "English",

volume = "16",

pages = "331--337",

journal = "PHARMACOGENETICS AND GENOMICS",

issn = "1744-6872",

publisher = "Lippincott Williams and Wilkins",

number = "5",

}

Wijpkema, JS, van Haelst, PL, Monraats, PS, Bruinenberg, M, Zwinderman, AH, Zijlstra, F, van der Steege, G, de Winter, RJ, Doevendans, PAFM, Waltenberger, J, Jukema, JW & Tio, RA 2006, 'Restenosis after percutaneous coronary intervention is associated with the angiotensin-II type-1 receptor 1166A/C polymorphism but not with polymorphisms of angiotensin-converting enzyme, angiotensin-II receptor, angiotensinogen or heme oxygenase-1', PHARMACOGENETICS AND GENOMICS, vol. 16, nr. 5, blz. 331-337.

Restenosis after percutaneous coronary intervention is associated with the angiotensin-II type-1 receptor 1166A/C polymorphism but not with polymorphisms of angiotensin-converting enzyme, angiotensin-II receptor, angiotensinogen or heme oxygenase-1. / Wijpkema, JS; van Haelst, PL; Monraats, PS et al.
In: PHARMACOGENETICS AND GENOMICS, Vol. 16, Nr. 5, 05.2006, blz. 331-337.

Onderzoeksoutput: Article › Academic › peer review

TY - JOUR

T1 - Restenosis after percutaneous coronary intervention is associated with the angiotensin-II type-1 receptor 1166A/C polymorphism but not with polymorphisms of angiotensin-converting enzyme, angiotensin-II receptor, angiotensinogen or heme oxygenase-1

AU - Wijpkema, JS

AU - van Haelst, PL

AU - Monraats, PS

AU - Bruinenberg, M

AU - Zwinderman, AH

AU - Zijlstra, F

AU - van der Steege, G

AU - de Winter, RJ

AU - Doevendans, PAFM

AU - Waltenberger, J

AU - Jukema, JW

AU - Tio, RA

N1 - 0 Article J

PY - 2006/5

Y1 - 2006/5

N2 - Objectives The renin-angiotensin system (RAS) is thought to play a major role in the pathophysiology of de-novo restenotic lesions and in-stent restenosis after percutaneous coronary intervention (PCI). Heme oxygenase-1 (HO-1), is thought to beneficially influence these processes. We examined the effect of pharmacologic as well as genetic RAS interactions on restenosis in a large population of consecutive patients undergoing PCI, and evaluated possible gene-gene interactions in both systems.Methods The GENDER project is a multicenter prospective follow-up study, including 3146 patients after successful PCI. Genotyping in these patients was performed for the ACE gene insertion/deletion, the angiotensinogen 235Met/Thr, T174M and A(-6)G, the angiotensin-II type 1 receptor (AT1R) 1166A/C and T81OA, the angiotensin-II type 2 receptor (AT2R) 1675G/A and 3123A polymorphisms and the length polymorphism in the HO-1 promoter region.Results A total of 3104 patients were followed for 10 months. In 2975 patients at least one of the nine genotypes could be determined. The AT1R 1166 CC genotype showed a significant association with TVR; the other polymorphisms did not. RAS-inhibitory drugs were not associated with the incidence of TVR, nor did they interact with any of the investigated polymorphisms. Patients with the ACE I/I polymorphism showed a trend towards a better outcome if they had a short number of repeats in the HO-1 promoter. This relationship was inversely present in carriers of the ACE D/D polymorphism.Conclusion We could only establish a role for the AT1R 1166A/C polymorphism in restenosis after PCI. However, significant gene-gene interaction was suggested for the ACE gene and the HO-1 promotor. The RAS and HO-1 relation in restenosis merits further investigation. Pharmacogenetics and Genomics 16:331-337 (c) 2006 Lippincott Williams & Wilkins.

AB - Objectives The renin-angiotensin system (RAS) is thought to play a major role in the pathophysiology of de-novo restenotic lesions and in-stent restenosis after percutaneous coronary intervention (PCI). Heme oxygenase-1 (HO-1), is thought to beneficially influence these processes. We examined the effect of pharmacologic as well as genetic RAS interactions on restenosis in a large population of consecutive patients undergoing PCI, and evaluated possible gene-gene interactions in both systems.Methods The GENDER project is a multicenter prospective follow-up study, including 3146 patients after successful PCI. Genotyping in these patients was performed for the ACE gene insertion/deletion, the angiotensinogen 235Met/Thr, T174M and A(-6)G, the angiotensin-II type 1 receptor (AT1R) 1166A/C and T81OA, the angiotensin-II type 2 receptor (AT2R) 1675G/A and 3123A polymorphisms and the length polymorphism in the HO-1 promoter region.Results A total of 3104 patients were followed for 10 months. In 2975 patients at least one of the nine genotypes could be determined. The AT1R 1166 CC genotype showed a significant association with TVR; the other polymorphisms did not. RAS-inhibitory drugs were not associated with the incidence of TVR, nor did they interact with any of the investigated polymorphisms. Patients with the ACE I/I polymorphism showed a trend towards a better outcome if they had a short number of repeats in the HO-1 promoter. This relationship was inversely present in carriers of the ACE D/D polymorphism.Conclusion We could only establish a role for the AT1R 1166A/C polymorphism in restenosis after PCI. However, significant gene-gene interaction was suggested for the ACE gene and the HO-1 promotor. The RAS and HO-1 relation in restenosis merits further investigation. Pharmacogenetics and Genomics 16:331-337 (c) 2006 Lippincott Williams & Wilkins.

KW - angiotensins

KW - renin-angiotensin system

KW - hemeoxygenase 1

KW - single nucleotide polymorphism

KW - coronary restenosis

KW - angioplasty

KW - PLACEBO-CONTROLLED TRIAL

KW - MICROSATELLITE POLYMORPHISM

KW - ARTERY DISEASE

KW - BLOOD-PRESSURE

KW - GENE PROMOTER

KW - BALLOON ANGIOPLASTY

KW - RISK-FACTORS

KW - DOUBLE-BLIND

KW - IN-VIVO

KW - SYSTEM

M3 - Article

SN - 1744-6872

VL - 16

SP - 331

EP - 337

JO - PHARMACOGENETICS AND GENOMICS

JF - PHARMACOGENETICS AND GENOMICS

IS - 5

ER -

Wijpkema JS, van Haelst PL, Monraats PS, Bruinenberg M, Zwinderman AH, Zijlstra F et al. Restenosis after percutaneous coronary intervention is associated with the angiotensin-II type-1 receptor 1166A/C polymorphism but not with polymorphisms of angiotensin-converting enzyme, angiotensin-II receptor, angiotensinogen or heme oxygenase-1. PHARMACOGENETICS AND GENOMICS. 2006 mei;16(5):331-337.